MedTrace Logo

Antibiotic Prophylaxis for TEVAR

NCT05405790 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 457

Last updated 2025-09-25

No results posted yet for this study

Summary

The infection rate of thoracic endovascular aortic repair (TEVAR) is unknown due to a lack of epidemiological data. The rate currently available comes from researches conducted decades ago, when open surgery was the standard of care. Because of the potentially fatal consequences of a stent graft infection in the thoracic aorta, the investigators tend to prescribe antibiotic prophylaxis for at least three days. In this study, the investigators are going to collect data on patients receiving TEVAR in the past five years and provide the following information: a. the infection rate (MAGIC classification), b. the rate of fever, c. the results of the lab tests, such as the WBC count and C-reaction protein. d. risk factors associated with infection and fever.

Conditions

  • Aortic Dissection
  • Aortic Diseases
  • Aortic Aneurysm, Thoracic
  • Coarctation of Aorta
  • Hematoma; Aorta

Interventions

PROCEDURE

thoracic endovascular aortic repair

In The TEVAR procedure, we implant a stent graft into the diseased area of the thoracic artery, providing a route for the blood to flow within the stent graft and excluding the diseased aorta.

Sponsors & Collaborators

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-01-01
Completion
2025-09-01

Countries

  • China

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05405790 on ClinicalTrials.gov